Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1220310 | 0.98 | KMT2A (0.52) | ALDH1A1KMT2AATMHPGDRAB9A | |
| SCHEMBL13450960 | 0.98 | KMT2A (0.52) | ALDH1A1KMT2AATMHPGDRAB9A | |
| SCHEMBL11406691 | 0.95 | — | — | |
| SCHEMBL14010813 | 0.90 | — | — | |
| SCHEMBL8402970 | 0.90 | ALDH1A1 (0.51) | ALDH1A1KMT2AHPGDL3MBTL1SMN1; SMN2 | |
| SCHEMBL12706418 | 0.82 | ALDH1A1 (0.44) | ALDH1A1KMT2AHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL14590566 | 0.82 | ALDH1A1 (0.51) | ALDH1A1KMT2AL3MBTL1CYP1A2TSHR | |
| SCHEMBL508614 | 0.82 | GAA (0.51) | ALDH1A1KMT2AATML3MBTL1SMN1; SMN2 | |
| SCHEMBL508613 | 0.82 | MAPT (0.46) | ALDH1A1KMT2AHPGDL3MBTL1SMN1; SMN2 | |
| SCHEMBL3053299 | 0.82 | ALDH1A1 (0.47) | ALDH1A1KMT2AHPGDL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112313239-B | Immobilized ruthenium-TRIPHOS catalysts for selective hydrogenation of amides | 伊士曼化工公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-10-12 | — | — | US | disclosed |
| CN-112105623-B | Molecular catalysts for selective hydrogenolysis of amides | 伊士曼化工公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-3814362-B1 | IMMOBILIZED RUTHENIUM-TRIPHOS CATALYSTS FOR SELECTIVE HYDROGENOLYSIS OF AMIDES | EASTMAN CHEM CO (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3794004-B1 | MOLECULAR CATALYSTS FOR SELECTIVE HYDROGENOLYSIS OF AMIDES | EASTMAN CHEM CO (US) | 2022-11-09 | — | — | EP | disclosed |
| WO-2022219246-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2022-10-20 | — | — | WO | disclosed |
| US-20220324819-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2022-10-13 | — | — | US | disclosed |
| US-11274083-B2 | Substituted thiophenyl uracils, salts thereof and the use thereof as herbicidal agents | SYNGENTA CROP PROTECTION AG (CH) | 2022-03-15 | — | — | US | disclosed |
| EP-3728235-B1 | SUBSTITUTED THIOPHENYLURACILS , THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2022-02-09 | — | — | EP | disclosed |
| US-7531537-B2 | Benzofuran derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2009001089-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-12-31 | — | — | WO | disclosed |
| US-20080193413-A1 | Anti-Infective Agents | ABBOTT LABORATORIES (US) | 2008-08-14 | — | — | US | disclosed |
| US-7378414-B2 | Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone | ABBOTT LABORATORIES (US) | 2008-05-27 | — | — | US | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
| US-20070027183-A1 | Inhibitors of microsomal triglyceride transfer protein and apo-B secretion | SURFACE LOGIX, INC. (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027183-A1 | Inhibitors of microsomal triglyceride transfer protein and apo-B secretion | SURFACE LOGIX, INC. (US) | 2007-02-01 | — | — | US | disclosed |
| US-4182743-A | CARRIER CONTAINING HYDROGEN PEROXIDE WATER AND HYDROPHILIC STABILIZER | PHILIP MORRIS INCORPORATED (US) | 1980-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274083-B2 | Substituted thiophenyl uracils, salts thereof and the use thereof as herbicidal agents | UNG, TYMP, TYMS | ALDH1A1 133/4885KMT2A 2855/4885ATM 3632/4885 |
| US-20080193413-A1 | Anti-Infective Agents | POLI, RPL5, POLRMT | ALDH1A1 2554/4885KMT2A 4638/4885ATM 4152/4885 |
| US-20220324819-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | ALDH1A1 1137/4885KMT2A 3470/4885ATM 2697/4885 |
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | LIPC, CPT1A, CETP | ALDH1A1 1325/4885KMT2A 2865/4885ATM 1634/4885 |
| US-20070027183-A1 | Inhibitors of microsomal triglyceride transfer protein and apo-B secretion | APOB, CETP, MTTP | ALDH1A1 2890/4885KMT2A 3798/4885ATM 2266/4885 |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | ALDH1A1 258/4885KMT2A 2820/4885ATM 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.